Article published

The Founder, Dr. Festoff, published a paper in the August 2016 issue of the Journal of Neuroinflammation with colleagues Drs. Luca Cucullo and Ravi Sajji of the Texas Tech University Heath Sciences Center (TTUHSC) School of Pharmacy at Amarillo, TX, and Patrick van Dreden of Diagnostica Stago, Gennevilliers, France. The article was the result of work by PHLOGISTIX and the Blood Brain Research Center of TTUHSC, in association with the University of Kansas Medical Center (KUMC), that showed clear evidence that damage-associated molecules (DAMPs), amyloid beta peptide (Ab) and high mobility group box protein 1 (HMGB1), are elevated in the mild cognitive impairment (MCI) to Alzheimer’s disease (AD) continuum suggesting their potential use as biomarkers in pre-clinical AD diagnosis in at-risk populations (J. Neuroinflammation, 2016 Aug 24;13(1):194. doi: 10.1186/s12974-016-0670-z). These would include genetics-at–risk, age-at-risk and head injury-at-risk cohorts.